Skip to content

Perioperative Outcomes and Survival of Inflatable Video-Assisted Mediastinoscopic Transhiatal Esophagectomy for Selected Esophageal Cancer

Perioperative Outcomes and Survival of Inflatable Video-Assisted Mediastinoscopic Transhiatal Esophagectomy for Selected Esophageal Cancer: A Comparative Study With Propensity-Score Matching Analysis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07182266
Enrollment
1661
Registered
2025-09-19
Start date
2021-01-04
Completion date
2025-09-01
Last updated
2025-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Carcinoma

Keywords

esophageal carcinoma, mediastinoscopic, McKeown

Brief summary

Perioperative and oncologic benefits of inflatable video-assisted mediastinoscopic transhiatal esophagectomy (IVMTE) are unclear. This retrospective study aimed to compare the differences in perioperative outcomes and survival between IVMTE and video-assisted McKeown esophagectomy (VME).

Interventions

None listed

Sponsors

Shanghai Zhongshan Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

(I) primary esophageal cancer confirmed by endoscopic biopsy and (II) diagnosed resectable tumors based on positron emission tomography-computed tomography (PET-CT) according to the International Union Against Cancer Tumor, Node, Metastasis (TNM) Classification (8th edition)

Exclusion criteria

(I) presence of other advanced malignancies, (II) insufficient clinical data, or (III) postoperative follow-up of less than 12 months.

Design outcomes

Primary

MeasureTime frameDescription
Survivalwithin 2 years after surgeryDisease-Free Survival, Overall Survival
Complicationperioperativefollow the guidelines of the Esophageal Complications Consensus Group (ECCG) recommendations and Clavien-Dindo classification

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026